艾克司单抗治疗活动性放射学轴性脊柱关节炎52周疗效与安全性:COAST-V与COAST-W两项3期随机对照试验
两项3期随机对照试验评估艾克司单抗(IXE)治疗活动性放射学轴性脊柱关节炎(r-axSpA)患者至52周的疗效与安全性,纳入bDMARD初治(COAST-V)和TNFi经治(COAST-W)患者。结果显示IXE第16周的显著疗效维持至52周,安全性一致。
要点
- IXE在bDMARD初治和TNFi经治r-axSpA患者中第16周疗效维持至52周。
- COAST-V第52周ASAS40应答率:IXE Q4W 53%、IXE Q2W 51%、ADA/IXE 51%、PBO/IXE 47%。
- COAST-W第52周ASAS40应答率:IXE Q4W 34%、IXE Q2W 31%、PBO/IXE 39%。
核心结论
- 艾克司单抗第16周显示的显著疗效在bDMARD初治和TNFi经治r-axSpA患者中维持至52周。
- bDMARD初治患者初始使用阿达木单抗后换用艾克司单抗显示进一步数值改善。
- 艾克司单抗52周安全性与其已知安全性特征一致。
研究设计与样本
- COAST-V为3期随机对照试验,纳入活动性r-axSpA且bDMARD初治成人患者,按1:1:1:1随机(n=341)接受IXE Q2W、IXE Q4W、安慰剂或阿达木单抗Q2W。
- COAST-W为3期随机对照试验,纳入活动性r-axSpA且TNFi经治成人患者,按1:1:1随机(n=316)接受IXE Q2W、IXE Q4W或安慰剂。
- 第16周时IXE组继续原治疗,安慰剂或阿达木单抗组按1:1再随机换用IXE Q2W或Q4W至第52周。
主要发现
- COAST-V第16周和第52周ASAS40应答率(意向治疗人群,无应答者填补):IXE Q4W为48%和53%,IXE Q2W为52%和51%,ADA/IXE为36%和51%,PBO/IXE为19%和47%。
- COAST-W第16周和第52周ASAS40应答率:IXE Q4W为25%和34%,IXE Q2W为31%和31%,PBO/IXE为14%和39%。
- 两种IXE方案在疾病活动度、身体功能、炎症客观标志物、生活质量、健康状况和整体功能方面的改善维持至52周。
- 艾克司单抗52周安全性与其16周安全性一致。
关键数值与推荐
- COAST-V第52周ASAS40应答率:IXE Q4W 53%,IXE Q2W 51%,ADA/IXE 51%,PBO/IXE 47%。
- COAST-W第52周ASAS40应答率:IXE Q4W 34%,IXE Q2W 31%,PBO/IXE 39%。
- COAST-V第16周ASAS40应答率:IXE Q4W 48%,IXE Q2W 52%,ADA 36%,PBO 19%。
- COAST-W第16周ASAS40应答率:IXE Q4W 25%,IXE Q2W 31%,PBO 14%。
临床怎么用
- 对于活动性r-axSpA患者,无论bDMARD初治还是TNFi经治,艾克司单抗治疗至52周可维持疗效且安全性一致。
- bDMARD初治患者若初始使用阿达木单抗,换用艾克司单抗后仍可见进一步数值改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). METHODS: Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52. RESULTS: In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non-responder imputation) at weeks 16 and 52 were 48% and 53% (IXE Q4W); 52% and 51% (IXE Q2W); 36% and 51% (ADA/IXE); 19% and 47% (PBO/IXE). Corresponding ASAS40 response rates in COAST-W were 25% and 34% (IXE Q4W); 31% and 31% (IXE Q2W); 14% and 39% (PBO/IXE). Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks. Safety through 52 weeks of ixekizumab was consistent with safety through 16 weeks. CONCLUSION: The significant efficacy demonstrated with ixekizumab at week 16 was sustained for up to 52 weeks in bDMARD-naive and TNFi-experienced patients. bDMARD-naive patients initially treated with ADA demonstrated further numerical improvements after switching to ixekizumab. Safety findings were consistent with the known safety profile of ixekizumab. TRIAL REGISTRATION NUMBER: NCT02696785/NCT02696798.
引用
- Dougados M, Wei JC, Landewé R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2019. PMID: 31685553. doi:10.1136/annrheumdis-2019-216118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。